| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Mestranol |
Is a |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing quinestrol (medicinal product) |
Is a |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Mestranol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing quinestrol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinylestradiol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Ethinyloestradiol adverse reaction |
Causative agent (attribute) |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Allergy to ethinylestradiol |
Causative agent (attribute) |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol [endocrine] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 10 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 50 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 20 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol [malignancy] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol 50micrograms tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol 0.02mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely drospirenone 3 milligram and ethinylestradiol 30 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 20 microgram and levonorgestrel 100 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 30 microgram and levonorgestrel 50 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 125 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + levonorgestrel 0.03mg/0.15mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 40 microgram and levonorgestrel 75 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl oestradiol + levonorgestrel 0.05mg/0.25mg pills |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norethisterone 400 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing only ethinyl estradiol 0.035 mg and norethisterone 0.5 mg/1 each oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 35 microgram and norethisterone 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 50 microgram and norethisterone 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl oestradiol + norethindrone acetate 20mcg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + norethindrone acetate 30mcg/1.5mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 30 microgram and norgestrel 300 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + norgestrel 0.05mg/0.5mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Norelgestromin+ethinyl estradiol 6mg/0.75mg patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+desogestrel 20micrograms/150micrograms tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desogestrel 150 microgram and ethinylestradiol 30 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 30 microgram and levonorgestrel 150 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+levonorgestrel 30micrograms/250micrograms tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 50 microgram and levonorgestrel 250 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norethisterone 500 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+norethisterone 35micrograms/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 20 microgram and norethisterone acetate 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 30 microgram and norethisterone acetate 1.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+gestodene 30micrograms/75micrograms tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+gestodene+placebo 30micrograms/75micrograms tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 20 microgram and gestodene 75 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norgestimate 250 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 20mcg+progestogen (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 30mcg+progestogen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35mcg+progestogen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 50mcg+progestogen (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Phased cocs -ethinylestradiol+gestodene |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Phased cocs -ethinylestradiol+norethisterone-(biphasic) (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desogestrel + ethinyl estradiol + ethinyl oestradiol 0.15mg/0.01mg/0.01mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desogestrel + ethinyl oestradiol 0.15mg/0.03mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and etynodiol diacetate 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl oestradiol + ethynodiol diacetate 50mcg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + ferrous fumarate + norgestrel 0.03mg/75mg/0.3mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol+drospirenone 30micrograms/3mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norethisterone 750 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + levonorgestrel 0.15mg/0.03mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing only ethinylestradiol 0.03 milligram and drospirenone 3 milligram/1 each oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol 600micrograms / norelgestromin 6mg transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol- and norelgestromin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Ethinyl estradiol + etonogestrel 2.7mg/11.7mg vaginal ring |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Quinestrol (substance) |
Is a |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cervical ripening with ethinyl oestradiol |
Direct substance |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely desogestrel 100 microgram and ethinylestradiol 25 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 5 microgram and norethisterone acetate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 20 microgram and ferrous fumarate 75 mg and norethisterone 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 30 microgram and ferrous fumarate 75 milligram and norethisterone 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norgestimate 180 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinylestradiol and norgestimate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing ethinylestradiol and norethisterone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing desogestrel and ethinylestradiol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing ethinyl estradiol and ethynodiol diacetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinylestradiol and levonorgestrel (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Norethindrone + ethinyl oestradiol + ferrous fumarte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol + norgestimate 0.035mg/0.25mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aranelle |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinylestradiol and norgestrel (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Lutera 28 tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol 600micrograms / norelgestromin 6mg transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 2.5 microgram and norethisterone acetate 500 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing drospirenone and ethinylestradiol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely drospirenone 2 milligram and estradiol 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinyl estradiol 0.02mg / norelgestromin 0.15mg per day transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cyproterone acetate and ethinylestradiol adverse reaction |
Causative agent (attribute) |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Allergy to cyproterone acetate and ethinylestradiol |
Causative agent (attribute) |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cyproterone acetate 2 mg and ethinylestradiol 35 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cyproterone acetate+ethinyloestradiol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinylestradiol and gestodene (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Drospirenone 3 mg and ethinylestradiol 20 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ethinyl estradiol and norethisterone acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norgestimate 215 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 20 microgram and levonorgestrel 90 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desogestrel 150 microgram and ethinylestradiol 25 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 30 microgram and norethisterone acetate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ethinylestradiol 35 microgram and norethisterone acetate 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cervical ripening with ethinyl oestradiol |
Direct substance |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely desogestrel 125 microgram and ethinylestradiol 25 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drospirenone 3 mg and ethinylestradiol 20 microgram and levomefolate calcium 451 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ethinylestradiol 10 microgram and norethisterone 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Allergy to ethinylestradiol |
Causative agent (attribute) |
True |
Ethinylestradiol (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]